
CLAIMS

We claim:

1. A pharmaceutical composition comprising



(Conjugate **57**) or a pharmaceutically acceptable salt thereof, acetate buffer, mannitol, and solutol.

2. The pharmaceutical composition of claim 1, wherein the acetate buffer has a strength of at least 30mM.

3. The pharmaceutical composition of claim 1, wherein the acetate buffer has a strength of at least 40mM.

4. The pharmaceutical composition of claim 1, wherein the mannitol has a concentration of about 5%.

5. The pharmaceutical composition of claim 1, wherein the solutol has a concentration of about 2%.

6. A method of treating tumor comprising administering Conjugate **57** or a pharmaceutically acceptable salt thereof to a subject in need thereof, wherein the dose of Conjugate **57** is based on the body surface area (BSA) of the subject, and wherein the dose of Conjugate **57** is 8.8 mg/m^2 or less than 8.8 mg/m^2.

7. The method of claim 6, wherein the tumor is a neuroendocrine tumor (NET).

8. The method of claim 6, wherein the tumor selected from the group

consisting of gastroenteropancreatic (GEP), gastrointestinal (GI), pancreatic, lung, prostate, and thymus neuroendocrine tumor.

9. The method of claim 6, wherein the tumor is small cell lung cancer (SCLC) or large cell neuroendocrine carcinoma (LCNEC) of the lung.